U P-glycoprotein polymorphism and levothyroxine bioavailability in hypothyroid patients

Oztas E., Garcia-Saavedra A. P., Yanar F., Ozcinar B., Aksakal N., Purisa S., ...More

SAUDI PHARMACEUTICAL JOURNAL, vol.26, no.2, pp.274-278, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.1016/j.jsps.2017.11.012
  • Journal Name: SAUDI PHARMACEUTICAL JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.274-278
  • Keywords: P-glycoprotein, MDR1 polymorphisms, Levothyroxine, Hypothyroidism, MULTIDRUG-RESISTANCE GENE, SINGLE-NUCLEOTIDE POLYMORPHISMS, MDR1 GENE, ABCB1 POLYMORPHISMS, THYROID-DISEASE, ANTIRETROVIRAL THERAPY, TRANSPORTER GENE, DRUG DISPOSITION, EXPRESSION, PHARMACOKINETICS
  • Istanbul University Affiliated: Yes

Abstract

Objectives: P-glycoprotein (P-gp) contributes to the disposition of a wide variety of drugs; therefore, single nucleotide polymorphisms (SNPs) in the P-gp coding gene might affect its activity. It is well known that personalized medicine, instead of empirical treatment, is a clinically important approach for enhancing responses among patients. Indeed, there is a need to evaluate the association between SNPs of P-gp encoded multidrug resistance genes (MDR1, ABCB1), and the dosage requirements of these drugs. In the present study, we evaluated the association between the dosage of Levothyroxine (L-T4) and three common SNPs (C1236T, G2677T/A and C3435T).